Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Child developmental issues news

Show

From To
Babies born to mums with HIV face higher risks even though they’re HIV negative

HIV-uninfected children born to mothers with HIV are prone to infections that are more severe, are at almost two times greater risk of dying before their first birthday, and are more likely to be born prematurely than children born to mothers without HIV.

Published
29 November 2018
From
The Conversation
Hepatitis C increases the risk of premature delivery for pregnant women with HIV

Co-infection with hepatitis C greatly increases the risk of pre-term delivery for pregnant women with HIV, Polish researchers reported this week at the International Congress on Drug

Published
02 November 2018
By
Keith Alcorn
Neural tube defects and integrase inhibitors: studies show no further evidence of increased risk

No further evidence of an increased risk of infant neural tube defects related to the use of dolutegravir or other integrase inhibitors in early pregnancy has emerged

Published
30 October 2018
By
Keith Alcorn
Dolutegravir Use During Pregnancy: What Are the Risks?

Infectious Disease Advisor spoke to Rebecca M. Zash, MD, a co-investigator of the interim analysis by the Tsepamo Study in Botswana, which was published in the New England Journal of Medicine in July.

Published
22 October 2018
From
Infectious Disease Advisor
Efavirenz, but not dolutegravir, linked to neurological problems in children

Children born to HIV-positive women who take efavirenz (Sustiva or Stocrin, also a component of Atripla) during pregnancy are at greater risk of developing neurological disorders, some of

Published
11 October 2018
By
Liz Highleyman
Efavirenz in HIV-positive pregnant women, risk of neurological condition in children

Researchers found children of women whose ART regimen included efavirenz were 60 percent more likely to develop a neurological condition, such as microcephaly (small head), seizures (from a high fever or other cause) and eye abnormalities than children whose mothers took other ART medications.

Published
05 October 2018
From
IDSA press release
Developmental problems of children born to women with HIV linked to substance use and HIV, not antiretrovirals

Pre-term births and developmental problems in children born to mothers with HIV are associated with HIV infection, substance use and smoking, Canadian researchers have reported in

Published
11 September 2018
By
Keith Alcorn
Some antiretroviral regimens associated with pre-term birth and low birth weight

Exposure to protease inhibitor (PI)-based regimens and non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens may each be linked to low birth weight and pre-term births in infants

Published
03 September 2018
By
Keith Alcorn
Why the world may force women to choose: No birth control, no ARVs

A new drug could save 25 000 women living with HIV but could it come at the cost of their babies lives?

Published
22 August 2018
From
Bhekisisa
Dolutegravir-based ART recommended for all – if reliable contraception is available

The World Health Organization (WHO) has issued new antiretroviral treatment guidelines recommending dolutegravir-based treatment as the preferred first-line treatment option for all adults, adolescents and children, including

Published
24 July 2018
By
Keith Alcorn
← First12345...7Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.